FETOPLACENTAL ANGIOGENESIS IN PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY
Abstract
The article presents the results of the studing of fetoplacental angiogenesis, as the reason of placenta malfunction and featus progress.
The objective: the examination included 116 pregnant famale patients with placental insufficiency and growth retardation syndrome and 52 pregnant famale patients with physiological pregnancy. Results: it was determined that proangiogenic vessel factor – placental growth factor (P1GF) and angiogenic vessel factors are the soluble fms-like tyrozinkinaze (sFlt-1) and soluble endogline (sEng). There was determined angiogenic coefficient – Ka, calculated in formule sFlt-1/PlGF×10.
Conclusion: it was revealed that placental insufficiency characterized falure balance of vessel growth factors, enlarged levels of angiogenic vessel factors and low levels of proangiogenic factor. For the development of placental insufficiency and enlarged stage of growth retardation syndrome the increasion of angiogenic coefficient Ka is typical.
The objective: the examination included 116 pregnant famale patients with placental insufficiency and growth retardation syndrome and 52 pregnant famale patients with physiological pregnancy. Results: it was determined that proangiogenic vessel factor – placental growth factor (P1GF) and angiogenic vessel factors are the soluble fms-like tyrozinkinaze (sFlt-1) and soluble endogline (sEng). There was determined angiogenic coefficient – Ka, calculated in formule sFlt-1/PlGF×10.
Conclusion: it was revealed that placental insufficiency characterized falure balance of vessel growth factors, enlarged levels of angiogenic vessel factors and low levels of proangiogenic factor. For the development of placental insufficiency and enlarged stage of growth retardation syndrome the increasion of angiogenic coefficient Ka is typical.
About the Authors
O. V. Makarov
Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation (Moscow)
Russian Federation
Russian Federation
E. V. Volkova
Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation (Moscow)
Russian Federation
Russian Federation
E. Yu. Lysyuk
Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation (Moscow)
Russian Federation
Russian Federation
Yu. V. Kopylova
Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation (Moscow)
Russian Federation
Russian Federation
References
1. Евсеева З.П., Сагамонова К.Ю., Палиева Н.В., Заманская Т.А., Маркарьян И.В., Мелконов Э.Ю. Критерии ранней диагностики фетоплацентарной недостаточности и синдрома задержки роста плода. Российский вестник акушера-гинеколога. 2008; 3: 12-21.
2. Крымшокалова З.С., Орлов В.И., Подгорная O.A., Щекатурина Е.В. Оценка маточноплацентарного и фетоплацентарного кровотока при задержке роста плода. Российский вестник акушера-гинеколога. 2008; 3: 67-77.
3. Кузьмин В.Н. Фетоплацентарная недостаточность: проблема современного акушерства. Лечащий врач. 2011; 3: 50-54.
4. Кулаков В.И., Орджоникидзе Н.В., Тютюнник В.Л. Плацентарная недостаточность и инфекция. Руководство для врачей. М. 2004; 494 с.
5. Макацария А.Д., Бицадзе В.О., Баймурадова С.М., Передеряева Е.Б., Пшеничникова Т.Б., Хизроева Д.Х., Донина Е.В., Акиныпина С.В. Профилактика повторных осложнений беременности в условиях тромбофилии. Руководство для врачей. М. 2008; 152 с.
6. Милованов А.П., Савельева С.В. Внутриутробное развитие человека: руководство для врачей. М. 2006; 384 с.
7. Николаева Л.Б., Тришкин А.Г., Колядов В.А. Эхографические и морфологические особенности плаценты у первородящих женщин. Российский вестник акушера-гинеколога. 2009; 4: 3-6.
8. Савельева Г.М., Курцер М.А., Шалина Р.И. Материнская смертность и пути ее снижения. Акушерство и гинекология. 2009; 3: 11-15.
9. Соколов Д.И. Васкулогенез и ангиогенез в развитии плаценты // Журнал акушерства и женских болезней. 2007; 3.
10. Стрижаков А.Н., Кузьмина Т.Е. Беременность после кесарева сечения: течение, осложнения, исходы. Вопросы гинекологии, акушерства и перинатологии. 2002; 1 (2): 40-46.
11. Стрижаков А.Н., Мусаев З.М., Тимохина Т.Ф., Наумчик Б.И., Буданцева А.В., Системные нарушения гемодинамики при синдроме задержки роста плода как фактор риска гипоксически-ишемических поражений ЦНС и отклонений психомоторного развития детей. Акушерство и гинекология. 2003; 1: 11-6.
12. Burton G.I., Charnock-Jones D.S., Jauniaux E. Regulation of vascular growth and function in the human placenta. Reproduction. 2009; 138: 895-902.
13. Guillermina Girardi, Dmitry Yarilin. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction, 2006.
14. Malamitsi-Puchner A., Boutsikou T., Economou E., Sarandakou A., Makrakis E., Hassiakos D., Creatsas G. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm. 2005 Oct. 24; (5): 293-7.
15. Mandruzzato G.P., Intrauterine growth restriction (IUGR): guidelines for definition, recognition and management, Archives of Perinatal Medicine. 2008; 14: 7-8.
16. Mitra S.C., Seshan S.V., Riachi L.E. Placental vessel morphometry in growth retardation and increased resistance of the umbilical artery Doppler flow. J. Matern. Fetal. Med. 2000 SepOct; 9 (5): 282-6.
17. Redman C.W. Sargent II.: Latest advances in understanding preeclampsia. Science 2005; 308: 1592-4.
18. Romero R. et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal. Neonatal. Med. 2008; 21 (1): 9-23.
19. Romero R., Erez O., Espinoza J. et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J. Matern. Fetal. Neonatal. Med. 2008; 21 (5): 279-287.
20. Smotrich D.B., Stilman R.G., Widra E.A., Gindoff P.R., Kaplan P., Graubert M., Johnson K.E. Immunocytochemical localization of growth factors and their receptors in human pre-embryos and Fallopian tubes. Hum. Reprod. 1996; 11 (1): 184-190.
21. Sugino N., Kashida S., Karube-Harada A., Takiguchi S., Kato H. Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy. Reproduction. 2002 Mar; 123 (3): 379-87.
22. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A., Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 2003 Apr 11; 278 (15): 12605-8. Epub 2003 Jan 21.
23. Wallner W., Sengenberger R., Strick R. et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci (Lond). 2007; 112 (1): 51-57.
Review
For citations:
Makarov O.V., Volkova E.V., Lysyuk E.Yu., Kopylova Yu.V. FETOPLACENTAL ANGIOGENESIS IN PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY. Obstetrics, Gynecology and Reproduction. 2013;7(3):13-19. (In Russ.)
Views: 449
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
